Related Experiment Videos
Summary
Plasma derivatives can be classified by viral hepatitis transmission risk. Heating or adding antibodies effectively reduces hepatitis B and non-A, non-B hepatitis risks in these products.
Area of Science:
- Biochemistry
- Immunology
- Virology
Background:
- Plasma derivatives pose a risk of viral hepatitis transmission, primarily Hepatitis B and non-A, non-B hepatitis.
- Donor screening for Hepatitis B surface antigen (HBsAg) reduces but does not eliminate transmission risk.
Purpose of the Study:
- To evaluate methods for reducing viral hepatitis transmission risk from plasma derivatives.
- To assess the efficacy of heat treatment and antibody addition in mitigating hepatitis risks.
Main Methods:
- Categorization of plasma derivatives into low-risk and high-risk groups based on manufacturing processes.
- Analysis of heat treatment protocols (60°C for 10 hours) for low-risk products like Albumin and Plasma Protein Fraction.
- Evaluation of antibody inclusion (Immune Globulin, anti-HBs) and potential addition of antibodies against non-A, non-B hepatitis agents.
- Assessment of stabilization and heating methods for high-risk derivatives, including AHF, Factor IX, AT-III, and others.
Main Results:
- Low-risk products (Albumin, Plasma Protein Fraction, Immune Globulin) demonstrate minimal risk due to inherent protective factors (heat, antibodies).
- HBsAg screening alone is insufficient to eliminate Hepatitis B risk from plasma derivatives.
- Combination of stabilization and heating, or addition of anti-HBs, can further reduce Hepatitis B risk.
- Potential addition of antibodies against non-A, non-B hepatitis agents could prevent transmission of both viral types.
- Heat and stabilization methods show potential for inactivating both Hepatitis B and non-A, non-B hepatitis infectivity in high-risk products.
Conclusions:
- Plasma derivative safety regarding viral hepatitis can be significantly enhanced through specific manufacturing and treatment strategies.
- Heat treatment and antibody inclusion are key to minimizing hepatitis transmission risks.
- Further research into antibody development for non-A, non-B hepatitis is warranted to ensure comprehensive safety.